{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:20:15Z","timestamp":1780554015006,"version":"3.54.1"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir\/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/im9.0000000000000033","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T19:34:13Z","timestamp":1600716853000},"page":"89-95","source":"Crossref","is-referenced-by-count":2,"title":["Potential Therapeutic Options for COVID-19"],"prefix":"10.1097","volume":"2","author":[{"given":"Xiaoqin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9]]},"reference":[{"issue":"(7477)","key":"R1-20230926","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","article-title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor","volume":"503","author":"Ge","year":"2013","journal-title":"Nature"},{"issue":"(1)","key":"R2-20230926","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12250-016-3726-4","article-title":"Molecular mechanisms of coronavirus RNA capping and methylation","volume":"31","author":"Chen","year":"2016","journal-title":"Virol Sin"},{"issue":"(8)","key":"R3-20230926","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New Engl J Med"},{"issue":"(6)","key":"R4-20230926","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol"},{"issue":"(2)","key":"R5-20230926","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"(7)","key":"R6-20230926","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3201\/eid2607.200282","article-title":"High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2","volume":"26","author":"Sanche","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"(1)","key":"R7-20230926","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/ciz170","article-title":"Widespread use of high-dose ceftriaxone therapy for uncomplicated gonorrhea without reported ceftriaxone treatment failure: results from 5 years of multicenter surveillance data in China","volume":"70","author":"Han","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"(10223)","key":"R8-20230926","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"(18)","key":"R9-20230926","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"(4)","key":"R10-20230926","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","article-title":"Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines","volume":"326","author":"Morgenstern","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"(11)","key":"R11-20230926","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"(4)","key":"R12-20230926","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"(21)","key":"R13-20230926","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1001\/jama.289.21.JOC30885","article-title":"Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area","volume":"289","author":"Booth","year":"2003","journal-title":"JAMA"},{"issue":"(7594)","key":"R14-20230926","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"(396)","key":"R15-20230926","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res"},{"issue":"(3)","key":"R17-20230926","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"(10)","key":"R18-20230926","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engla J Med"},{"issue":"(24)","key":"R19-20230926","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"(3)","key":"R20-20230926","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-20230926","first-page":"400","article-title":"Unrevealing sequence and structural features of novel coronavirus using approaches: the main protease as molecular target","volume":"19","author":"Ortega","year":"2020","journal-title":"EXCLI J"},{"issue":"(3)","key":"R22-20230926","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"(5)","key":"R23-20230926","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-\u03b1 for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir Ther (Lond)"},{"issue":"(6)","key":"R24-20230926","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2014.07.026","article-title":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen","volume":"44","author":"Spanakis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"25359","DOI":"10.1038\/srep25359","article-title":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity","volume":"6","author":"Min","year":"2016","journal-title":"Sci Rep"},{"issue":"(19)","key":"R26-20230926","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"(6)","key":"R27-20230926","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"R28-20230926","article-title":"First clinical study using HCV protease inhibitor danoprevir to treat nai\u0308ve and experienced COVID-19 patients","author":"Chen","year":"2020","journal-title":"medRxiv"},{"issue":"(11)","key":"R29-20230926","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"(3)","key":"R30-20230926","doi-asserted-by":"crossref","first-page":"105923","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS-CoV-2","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"(11)","key":"R32-20230926","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/M20-1334","article-title":"Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know","volume":"172","author":"Yazdany","year":"2020","journal-title":"Ann Intern Med"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"(6)","key":"R34-20230926","doi-asserted-by":"crossref","first-page":"e008662","DOI":"10.1161\/CIRCEP.120.008662","article-title":"Effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection","volume":"13","author":"Saleh","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"(24)","key":"R35-20230926","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"issue":"(3S)","key":"R36-20230926","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.encep.2020.04.010","article-title":"Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study","volume":"46","author":"Plaze","year":"2020","journal-title":"Encephale"},{"key":"R37-20230926","doi-asserted-by":"crossref","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"issue":"(10)","key":"R38-20230926","first-page":"e112","article-title":"Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020","volume":"35","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"(8)","key":"R39-20230926","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/ijms21082948","article-title":"Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D","volume":"21","author":"La Vignera","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"(1)","key":"R40-20230926","doi-asserted-by":"crossref","first-page":"75","DOI":"10.18433\/jpps31069","article-title":"Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients","volume":"23","author":"Suba","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"R41-20230926","article-title":"Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction","author":"Liu","year":"2020","journal-title":"bioRxiv"},{"key":"R42-20230926","article-title":"The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15","author":"Matsuyama","year":"2020","journal-title":"bioRxiv"},{"key":"R43-20230926","article-title":"Novel and potent inhibitors targeting DHODH, a rate-limiting enzymein de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2","author":"Xiong","year":"2020","journal-title":"bioRxiv"},{"key":"R44-20230926","article-title":"A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19","author":"Ge","year":"2020","journal-title":"bioRxiv"},{"issue":"(Pt 11)","key":"R45-20230926","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1099\/vir.0.013599-0","article-title":"Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation","volume":"90","author":"Kuri","year":"2009","journal-title":"J Gen Virol"},{"issue":"(9385)","key":"R46-20230926","first-page":"748","article-title":"Treatment of SARS with human interferons (vol 362, pg 293, 2003)","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"issue":"(1)","key":"R47-20230926","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jiph.2017.08.009","article-title":"Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review","volume":"11","author":"Mustafa","year":"2018","journal-title":"J Infect Public Heal"},{"issue":"(10)","key":"R48-20230926","doi-asserted-by":"crossref","first-page":"e1002331","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS Pathog"},{"issue":"(SI-1)","key":"R49-20230926","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3906\/sag-2004-168","article-title":"COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs","volume":"50","author":"Tufan","year":"2020","journal-title":"Turk J Med Sci"},{"key":"R50-20230926","article-title":"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial","author":"Bian","year":"2020","journal-title":"bioRxiv"},{"issue":"(1)","key":"R51-20230926","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"(7)","key":"R52-20230926","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther (Lond)"},{"key":"R53-20230926","article-title":"The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study","author":"Duan","year":"2020","journal-title":"medRxiv"},{"issue":"(5)","key":"R54-20230926","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"Chembiochem"},{"key":"R55-20230926","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antivir Res"},{"issue":"(4)","key":"R56-20230926","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"issue":"(2)","key":"R57-20230926","doi-asserted-by":"crossref","first-page":"e30802","DOI":"10.1371\/journal.pone.0030802","article-title":"Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling","volume":"7","author":"Sun","year":"2012","journal-title":"Plos One"},{"key":"R58-20230926","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2013.11.040","article-title":"MERS-CoV papain-like protease has deISGylating and deubiquitinating activities","volume":"450","author":"Mielech","year":"2014","journal-title":"Virology"},{"key":"R59-20230926","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antivir Res"},{"issue":"(5)","key":"R60-20230926","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"R61-20230926","article-title":"X-ray structure of main protease of the novel coronavirus SARS-CoV-2 enables design of a-ketoamide inhibitors","author":"Zhang","year":"2020","journal-title":"bioRxiv"},{"key":"R62-20230926","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Research"},{"key":"R63-20230926","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"issue":"(1)","key":"R64-20230926","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2004.03.031","article-title":"Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase","volume":"324","author":"Lu","year":"2004","journal-title":"Virology"},{"issue":"(11)","key":"R65-20230926","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1016\/j.ejmech.2011.09.005","article-title":"2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV)","volume":"46","author":"Kim","year":"2011","journal-title":"Eur J Med Chem"},{"issue":"(2)","key":"R66-20230926","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2478\/acph-2020-0024","article-title":"Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors","volume":"70","author":"Zaher","year":"2020","journal-title":"Acta Pharmaceut"},{"issue":"(9)","key":"R67-20230926","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00957-12","article-title":"Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase","volume":"56","author":"Adedeji","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"(8)","key":"R68-20230926","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/AAC.02994-14","article-title":"Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and middle east respiratory syndrome coronaviruses","volume":"58","author":"Adedeji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"(2)","key":"R69-20230926","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"(1)","key":"R70-20230926","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/jcm8010006","article-title":"Advancements in nucleic acid based therapeutics against respiratory viral infections","volume":"8","author":"Asha","year":"2018","journal-title":"J Clin Med"},{"issue":"(5)","key":"R71-20230926","doi-asserted-by":"crossref","first-page":"e1004166","DOI":"10.1371\/journal.ppat.1004166","article-title":"Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus","volume":"10","author":"Lundin","year":"2014","journal-title":"PLoS Pathog"},{"issue":"(5)","key":"R72-20230926","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol"},{"issue":"(7798)","key":"R73-20230926","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"(1)","key":"R74-20230926","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"(1)","key":"R75-20230926","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"issue":"(6)","key":"R76-20230926","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"(2)","key":"R77-20230926","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"(4)","key":"R78-20230926","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res"},{"issue":"(4)","key":"R79-20230926","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkm301","article-title":"The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins","volume":"60","author":"van der Meer","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"(3)","key":"R80-20230926","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.antiviral.2006.10.008","article-title":"Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a\/7b, 3a\/3b and S","volume":"73","author":"Akerstrom","year":"2007","journal-title":"Antiviral Res"},{"issue":"(6)","key":"R81-20230926","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor","volume":"44","author":"Huentelman","year":"2004","journal-title":"Hypertension"},{"issue":"(1)","key":"R82-20230926","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virol.2006.01.029","article-title":"Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor","volume":"350","author":"Han","year":"2006","journal-title":"Virology"},{"issue":"(1)","key":"R83-20230926","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"R84-20230926","doi-asserted-by":"crossref","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res"},{"issue":"(42)","key":"R85-20230926","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1073\/pnas.1407087111","article-title":"Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein","volume":"111","author":"Millet","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R86-20230926","article-title":"LY6E impairs coronavirus fusion and confers immune control of viral disease","author":"Pfaender","year":"2020","journal-title":"bioRxiv"},{"issue":"(2)","key":"R87-20230926","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"(5)","key":"R89-20230926","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1152\/physiolgenomics.00033.2020","article-title":"Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease","volume":"52","author":"Golonka","year":"2020","journal-title":"Physiol Genomics"}],"container-title":["Infectious Microbes and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IM9.0000000000000033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T10:20:36Z","timestamp":1695723636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IM9.0000000000000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/im9.0000000000000033","relation":{},"ISSN":["2641-5917"],"issn-type":[{"value":"2641-5917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}